Galecto Inc. (GLTO) News

Galecto Inc. (GLTO): $0.50

0.01 (+1.32%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add GLTO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#180 of 361

in industry

Filter GLTO News Items

GLTO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GLTO News From Around the Web

Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeksBOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new and encouraging clinical data, including two additional partial responders, from the dose-finding Part A of its Phase 1b/2a t

Yahoo | October 23, 2023

Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst calls

Today's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly.

Yahoo | September 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

Galecto Announces Plans to Explore Strategic Alternatives

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Galecto

Yahoo | September 26, 2023

Galecto to Present at Investor Conferences in September

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings. H.C. Wainwright 25th Annual Global Investment ConferenceDate

Yahoo | August 31, 2023

OrbiMed Advisors LLC Reduces Stake in Galecto Inc

Firm real-time pick highlight

Yahoo | August 17, 2023

Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More

Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.

Yahoo | August 17, 2023

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.

Yahoo | August 16, 2023

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF). The GALACTIC-1 trial did n

Yahoo | August 15, 2023

Galecto Reports Second Quarter Operating and Financial Results

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2023. “Galecto has made strong clinical progress in the first half of the year, setting the stage for several important milestones during the rest of 2023. We completed dosing in our Phase 2b GALAC

Yahoo | July 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!